DE60215793D1 - Kombination eines gelatinasehemmers und eines anti-tumor-agent, und deren verwendung - Google Patents

Kombination eines gelatinasehemmers und eines anti-tumor-agent, und deren verwendung

Info

Publication number
DE60215793D1
DE60215793D1 DE60215793T DE60215793T DE60215793D1 DE 60215793 D1 DE60215793 D1 DE 60215793D1 DE 60215793 T DE60215793 T DE 60215793T DE 60215793 T DE60215793 T DE 60215793T DE 60215793 D1 DE60215793 D1 DE 60215793D1
Authority
DE
Germany
Prior art keywords
gelatinase
heather
combination
tumor agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60215793T
Other languages
English (en)
Other versions
DE60215793T2 (de
Inventor
Thomas Friess
Hans-Willi Krell
Werner Scheuer
Georg Tiefenthaler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60215793D1 publication Critical patent/DE60215793D1/de
Application granted granted Critical
Publication of DE60215793T2 publication Critical patent/DE60215793T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60215793T 2001-05-03 2002-04-30 Kombination eines gelatinasehemmers und eines anti-tumor-agent, und deren verwendung Expired - Fee Related DE60215793T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01110119 2001-05-03
EP01110119 2001-05-03
PCT/EP2002/004744 WO2002089824A1 (en) 2001-05-03 2002-04-30 Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof

Publications (2)

Publication Number Publication Date
DE60215793D1 true DE60215793D1 (de) 2006-12-14
DE60215793T2 DE60215793T2 (de) 2007-09-06

Family

ID=8177240

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215793T Expired - Fee Related DE60215793T2 (de) 2001-05-03 2002-04-30 Kombination eines gelatinasehemmers und eines anti-tumor-agent, und deren verwendung

Country Status (9)

Country Link
US (1) US20040132739A1 (de)
EP (1) EP1387689B1 (de)
JP (1) JP2004527568A (de)
CN (1) CN100338041C (de)
AT (1) ATE344041T1 (de)
CA (1) CA2444013A1 (de)
DE (1) DE60215793T2 (de)
ES (1) ES2274043T3 (de)
WO (1) WO2002089824A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
KR100771411B1 (ko) 2004-04-01 2007-10-30 에프. 호프만-라 로슈 아게 피리미딘-2,4,6-트리온의 시클로덱스트린 포접 복합체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548624A1 (de) * 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2002504916A (ja) * 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
IL143901A0 (en) * 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia

Also Published As

Publication number Publication date
CA2444013A1 (en) 2002-11-14
EP1387689A1 (de) 2004-02-11
CN100338041C (zh) 2007-09-19
ES2274043T3 (es) 2007-05-16
CN1505521A (zh) 2004-06-16
US20040132739A1 (en) 2004-07-08
EP1387689B1 (de) 2006-11-02
DE60215793T2 (de) 2007-09-06
ATE344041T1 (de) 2006-11-15
JP2004527568A (ja) 2004-09-09
WO2002089824A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
TW200420573A (en) Bifunctional heterocyclic compounds and methods of making and using same
DK2263694T3 (da) Antitumormiddel omfattende histon-deacetylase-inhibitoren FK228 og topoisomerase-II-inhibitoren doxorubicin
EP1399414A4 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
EE05417B1 (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
DK1663242T3 (da) 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
ES2176212T3 (es) Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
CY1106640T1 (el) Αναστολεις κρουζιπαϊνης και αλλων πρωτεασων κυστεϊνης
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
EA200301091A1 (ru) Противоопухолевые комбинации, такие как рапамицин вместе с гемцитабином или фторурацилом
CY1112630T1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
ATE380049T1 (de) Kombinationen enthaltend cgmp-pde5-hemmer.
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
DE60231295D1 (de) R und ppar modulatoren
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
DK1244650T3 (da) Arylaminderivater og deres anvendelse som antitelomerasemidler
SE0301650D0 (sv) Novel compounds
PL372769A1 (en) Cyanoguanidine prodrugs
DE60215793D1 (de) Kombination eines gelatinasehemmers und eines anti-tumor-agent, und deren verwendung
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
DE60130891D1 (de) Heilmittel für krebs
DE60304360D1 (de) N-aryl-2-oxazolidinone und deren derivate
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
MXPA04005226A (es) 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee